Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007852 · ClinicalTrials.gov registry record · Phase 2
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00007852 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 44 participants.
The verdict
NCT00007852, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL rituximab
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-09-01 |
| Est. Completion | 2011-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007852
The ClinicalTrials.gov registry entry for NCT00007852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00007852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00007852 about?
NCT00007852 is a clinical study titled "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemothera...
What is the current status of trial NCT00007852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2000-09-01. Estimated completion is 2011-01-01.
What interventions are being tested in trial NCT00007852?
The interventions under investigation include: rituximab (BIOLOGICAL), etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00007852?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.